Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06678552 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 2 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 3 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 4 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 5 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 6 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Name | Type | Description |
|---|---|---|
| PF-06678552 | DRUG | PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days. |
| Placebo | DRUG | PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days. |
| PF-06678552 or Placebo | DRUG | PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period. |
Inclusion Criteria: * Healthy male and/or female subjects of non-childbearing potential. * Body Mass Index (BMI) of 18 to 30.5 kg/m2; and a total body weight \>50 kg * Low density lipoprotein cholesterol between 115 mg/dL and 190 mg/dL Exclusion Criteria: * Evidence or history of clinically signi...
PF-06678552 is an investigational small molecule developed by Pfizer, Inc. It has been studied in Phase 1 clinical trials in healthy adult volunteers rather than in patients with a specific disease. No therapeutic indication for PF-06678552 has been disclosed.
PF-06678552 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored both of the Phase 1 studies conducted with this compound.
PF-06678552 is in Phase 1 clinical development. Both of its trials were Phase 1 studies, and both are now completed. There are no active trials of PF-06678552 listed, and the compound is investigational rather than approved.
PF-06678552 has been evaluated in two completed Phase 1 trials: NCT02079922, a multiple dose study in healthy subjects with 38 participants, and NCT01992614, a single dose study in healthy subjects with 24 participants. Both were conducted in Belgium and together enrolled 62 healthy volunteers.
Both PF-06678552 Phase 1 trials were randomized, double blind, and controlled studies in healthy adult volunteers aged 18 years and older. NCT02079922 tested multiple doses in 38 subjects, while NCT01992614 tested a single dose in 24 subjects. Both studies were run in Belgium and are completed.